Talphera (TLPH) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 03, 2020
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	351 Galveston Drive
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,324,147

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	[1]
Current Assets:
Cash and cash equivalents	$ 21,789	$ 14,684
Short-term investments	21,897	51,453
Accounts receivable, net	195	432
Inventories, net	2,639	3,295
Prepaid expenses and other current assets	2,099	1,824
Total current assets	48,619	71,688
Operating lease right-of-use assets	3,509	3,928
Property and equipment, net	14,488	14,552
Other assets	784	1,188
Total Assets	67,400	91,356
Current Liabilities:
Accounts payable	2,395	1,720
Accrued liabilities	3,749	5,528
Long-term debt, current portion	8,707	4,630
Deferred revenue, current portion	343	411
Operating lease liabilities, current portion	1,076	970
Liability related to the sale of future royalties, current portion	160	352
Total current liabilities	16,430	13,611
Long-term debt, net of current portion	17,324	20,517
Deferred revenue, net of current portion	0	2,833
Operating lease liabilities, net of current portion	3,092	3,640
Liability related to the sale of future royalties, net of current portion	90,042	91,683
Other long-term liabilities	644	490
Total liabilities	127,532	132,774
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value—200,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 80,890,185 and 79,573,101 shares issued and outstanding as of June 30, 2020 and December 31, 2019	80	79
Additional paid-in capital	360,425	356,609
Accumulated deficit	(420,637)	(398,106)
Total stockholders’ deficit	(60,132)	(41,418)
Total Liabilities and Stockholders’ Deficit	$ 67,400	$ 91,356
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	[1]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	80,890,185	79,573,101
Common stock, outstanding (in shares)	80,890,185	79,573,101
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Revenue	$ 2,924	$ 941	$ 3,310	$ 1,206
Operating costs and expenses:
Cost of goods sold	1,370	1,810	2,881	3,040
Research and development	813	1,163	2,225	2,540
Selling, general and administrative	7,575	11,329	20,886	21,305
Total operating costs and expenses	9,758	14,302	25,992	26,885
Loss from operations	(6,834)	(13,361)	(22,682)	(25,679)
Other income (expense):
Interest expense	(872)	(500)	(1,727)	(876)
Interest income and other (expense) income, net	270	456	205	1,083
Non-cash interest income (expense) on liability related to future sale of royalties	834	996	1,677	(611)
Total other income (expense)	232	952	155	(404)
Net loss before income taxes	(6,602)	(12,409)	(22,527)	(26,083)
Provision for income taxes	(4)	(3)	(4)	(3)
Net loss	(6,606)	(12,412)	(22,531)	(26,086)
Comprehensive loss	$ (6,606)	$ (12,412)	$ (22,531)	$ (26,086)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.08)	$ (0.16)	$ (0.28)	$ (0.33)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 12 (in shares)	80,661,853	78,902,470	80,359,679	78,845,944
Product [Member]
Revenue:
Revenue	$ 303	$ 768	$ 577	$ 894
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 2,621	$ 173	$ 2,733	$ 312

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018			78,757,930
Balance at Dec. 31, 2018	$ 153	$ 153	$ 78	$ 349,194	$ (345,019)	$ 4,253
Stock-based compensation				1,107		1,107
Issuance of common stock upon ESPP purchase (in shares)			85,135
Issuance of common stock upon ESPP purchase			$ 1	238		239
Net loss					(13,674)	(13,674)
Issuance of common stock upon exercise of stock options (in shares)			13,583
Issuance of common stock upon exercise of stock options				31		31
Balance (in shares) at Mar. 31, 2019			78,856,648
Balance at Mar. 31, 2019			$ 79	350,570	(358,540)	(7,891)
Balance (in shares) at Dec. 31, 2018			78,757,930
Balance at Dec. 31, 2018	$ 153	$ 153	$ 78	349,194	(345,019)	4,253
Net loss						(26,086)
Balance (in shares) at Jun. 30, 2019			78,914,170
Balance at Jun. 30, 2019			$ 79	352,454	(370,952)	(18,419)
Balance (in shares) at Mar. 31, 2019			78,856,648
Balance at Mar. 31, 2019			$ 79	350,570	(358,540)	(7,891)
Stock-based compensation				1,346		1,346
Net loss					(12,412)	(12,412)
Issuance of common stock upon exercise of stock options (in shares)			57,522
Issuance of common stock upon exercise of stock options				155		155
Issuance of warrants related to debt financing				383		383
Balance (in shares) at Jun. 30, 2019			78,914,170
Balance at Jun. 30, 2019			$ 79	352,454	(370,952)	(18,419)
Balance (in shares) at Dec. 31, 2019			79,573,101
Balance at Dec. 31, 2019			$ 79	356,609	(398,106)	(41,418)	[1]
Stock-based compensation				1,146		1,146
Restricted stock units vested (in shares)			216,399
Tax payments related to shares withheld for restricted stock units vested				(86)		(86)
Net proceeds from issuance of common stock in connection with equity financings (in shares)			431,800
Stock Issued During Period, Value, New Issues			$ 1	783		784
Issuance of common stock upon ESPP purchase (in shares)			194,451
Issuance of common stock upon ESPP purchase				218		218
Net loss					(15,925)	(15,925)
Balance (in shares) at Mar. 31, 2020			80,415,751
Balance at Mar. 31, 2020			$ 80	358,670	(414,031)	(55,281)
Balance (in shares) at Dec. 31, 2019			79,573,101
Balance at Dec. 31, 2019			$ 79	356,609	(398,106)	(41,418)	[1]
Net loss						(22,531)
Balance (in shares) at Jun. 30, 2020			80,890,185
Balance at Jun. 30, 2020			$ 80	360,425	(420,637)	(60,132)
Balance (in shares) at Mar. 31, 2020			80,415,751
Balance at Mar. 31, 2020			$ 80	358,670	(414,031)	(55,281)
Stock-based compensation				1,090		1,090
Restricted stock units vested (in shares)			29,434
Net proceeds from issuance of common stock in connection with equity financings (in shares)			445,000
Stock Issued During Period, Value, New Issues				665		665
Net loss					(6,606)	(6,606)
Balance (in shares) at Jun. 30, 2020			80,890,185
Balance at Jun. 30, 2020			$ 80	$ 360,425	$ (420,637)	$ (60,132)
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		57 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (6,606)	$ (15,925)	$ (12,412)	$ (13,674)	$ (22,531)	$ (26,086)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization					(121)	(118)
Non-cash interest (income) expense on liability related to royalty monetization	(834)		(996)		(1,677)	611	$ 29,858
Depreciation and amortization					979	734
Non-cash interest expense related to debt financing					558	234
Stock-based compensation					2,236	2,453
Other					341	(212)
Changes in operating assets and liabilities:
Accounts receivable					237	(172)
Inventories					277	(1,990)
Prepaid expenses and other assets					94	(946)
Accounts payable					675	559
Accrued liabilities					(1,779)	(164)
Operating lease liabilities					(442)	(313)
Deferred revenue					(2,901)	(149)
Net cash used in operating activities					(24,054)	(25,559)
Cash flows from investing activities:
Purchase of property and equipment					(170)	(1,790)
Purchase of investments					(28,807)	(28,156)
Proceeds from maturities of investments					58,555	19,700
Net cash provided by (used in) investing activities					29,578	(10,246)
Cash flows from financing activities:
Proceeds from issuance of long-term debt					0	25,000
Payment of costs in connection with refinancing of long-term debt					0	(190)
Payment of long-term debt					0	(3,470)
Extinguishment of debt					0	(8,864)
Net proceeds from issuance of common stock in connection with equity financings					1,449	0
Net proceeds from issuance of common stock through equity plans					218	425
Payment of employee tax obligations related to vesting of restricted stock units					(86)	0
Net cash provided by financing activities					1,581	12,901
Net increase (decrease) in cash and cash equivalents					7,105	(22,904)
Cash and cash equivalents—Beginning of period		$ 14,684		$ 87,975	14,684	87,975
Cash and cash equivalents—End of period	$ 21,789		$ 65,071		$ 21,789	$ 65,071	$ 21,789

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA ® TM ® November 2, 2018, first 2019. June 2018, not may one not The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. Although Zalviso was approved for sale in Europe on September 18, 2015, third November 2018 first 2019. DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Grünenthal Amended Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 14, 2020. On May 20, 2020, first third Termination of Proposed Acquisition of Tetraphase Pharmaceuticals, Inc. On March 15, 2020, May 27, 2020 May 29, 2020, On June 4, 2020, Co-Promotion Agreement On March 15, 2020, 15 not one July 28, 2020, no three six June 30, 2020. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, ARPI LLC, which was formed in September 2015 7 Reclassifications Certain prior year amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year's presentation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three six June 30, 2020, not may December 31, 2020. December 31, 2019, December 31, 2019, 10 10 December 31, 2019, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Restructuring Costs The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. On March 16, 2020, six June 30, 2020, The headcount reduction was completed in the first 2020. No Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2019. no six June 30, 2020, 2019 10 Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments – Credit Losses , ” 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022.

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents and short-term investments (in thousands): As of June 30 , 2020 Amortized Cost Gross Unrealized Gross Unrealized Fair Cash and cash equivalents: Cash $ 4,660 $ — $ — $ 4,660 Money market funds 1,334 — — 1,334 U.S. government agency securities 5,999 — — 5,999 Commercial paper 9,796 — — 9,796 Total cash and cash equivalents 21,789 — — 21,789 Short-term investments: U.S. government agency securities 13,052 — — 13,052 Commercial paper 8,845 — — 8,845 Total short-term investments 21,897 — — 21,897 Total cash, cash equivalents and short-term investments $ 43,686 $ — $ — $ 43,686 As of December 31, 2019 Amortized Cost Gross Unrealized Gross Unrealized Fair Cash and cash equivalents: Cash $ 1,957 $ — $ — $ 1,957 Money market funds 598 — — 598 Commercial paper 12,129 — — 12,129 Total cash and cash equivalents 14,684 — — 14,684 Short-term investments: U.S. government agency securities 14,268 — — 14,268 Commercial paper 27,131 — — 27,131 Corporate debt securities 10,054 — — 10,054 Total short-term investments 51,453 — — 51,453 Total cash, cash equivalents and short-term investments $ 66,137 $ — $ — $ 66,137 There were no June 30, 2020 December 31, 2019. No no three six June 30, 2020 June 30, 2019. As of June 30, 2020 December 31, 2019, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third June 30, 2020, December 31, 2019, 5 two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of June 30 , 2020 Fair Value Level I Level II Level III Assets Money market funds $ 1,334 $ 1,334 $ — $ — U.S. government agency securities 19,051 — 19,051 — Commercial paper 18,641 — 18,641 — Total assets measured at fair value $ 39,026 $ 1,334 $ 37,692 $ — Liabilities Contingent put option liability $ 591 $ — $ — $ 591 Total liabilities measured at fair value $ 591 $ — $ — $ 591 As of December 31, 2019 Fair Value Level I Level II Level III Assets Money market funds $ 598 $ 598 $ — $ — U.S. government agency securities 14,268 — 14,268 — Commercial paper 39,260 — 39,260 — Corporate debt securities 10,054 — 10,054 — Total assets measured at fair value $ 64,180 $ 598 $ 63,582 $ — Liabilities Contingent put option liability $ 437 $ — $ — $ 437 Total liabilities measured at fair value $ 437 $ — $ — $ 437 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three six June 30, 2020 June 30, 2019 ( Three Months 20 Six Months 20 Fair value—beginning of period $ 746 $ 437 Fair value of contingent put option associated with the Loan Agreement (155 ) 154 Fair value—end of period $ 591 $ 591 Three Months Six Months Fair value—beginning of period $ 98 $ 121 Fair value of contingent put option associated with the Loan Agreement 657 657 Change in fair value of contingent put option associated with the Prior Agreement (98 ) (121 ) Fair value—end of period $ 657 $ 657

Note 3 - Inventories, Net

Note 3 - Inventories, Net	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. , net Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of June 30 , 20 20 December 31, 201 9 Raw materials $ 693 $ 1,153 Work-in-process — 593 Finished goods 1,946 1,549 Total $ 2,639 $ 3,295 During the three six June 30, 2020, six June 30, 2020, may

Note 4 - Revenue from Contracts

Note 4 - Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. The following table summarizes revenue from contracts with customers for the three six June 30, 2020 2019 Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Product sales: DSUVIA $ 2 $ 157 Zalviso 301 420 Total product sales 303 577 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 37 121 Royalty revenue 12 40 Other revenue 2,572 2,572 Total revenues from contract and other collaboration 2,621 2,733 Total revenue $ 2,924 $ 3,310 Three Months Ended June 30, 20 19 Six Months Ended June 30, 20 19 Product sales: DSUVIA $ 55 $ 102 Zalviso 713 792 Total product sales 768 894 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 118 203 Royalty revenue 40 67 Other revenue 15 42 Total revenues from contract and other collaboration 173 312 Total revenue $ 941 $ 1,206 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2019. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. November 14, 2020. Contract and Other Collaboration Amended License Agreement Under the Amended License Agreement with Grünenthal, the Company is eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). Grünenthal will also make tiered royalty and supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the level of sales achieved, on net sales of Zalviso. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL BioPharma, Inc. or PDL, in connection with the Royalty Monetization. For additional information on the Royalty Monetization, see Note 7 Amended MSA Under the terms of the Amended MSA with Grünenthal, the Company will manufacture and supply the Product for use in the Field for the Territory exclusively for Grünenthal. The Product will be supplied at prices approximating the Company’s manufacturing cost, subject to certain caps, as defined in the MSA Amendment. The MSA Amendment requires the Company to use commercially reasonable efforts to enter stand-by contracts with third third As mentioned above, Grünenthal has exercised its right to terminate the Amended Agreements, effective on or about November 14, 2020. May 2020, no Contract Liability At June 30, 2020, November 14, 2020. The following table presents changes in the Company’s contract liability for the six June 30, 2020 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Amended Agreements $ 3,148 $ — $ (2,805 ) $ 343 Deferred revenue – Other 96 — (96 ) — Deferred revenue $ 3,244 $ — $ (2,901 ) $ 343 For the three six June 30, 2020 2019, Three Months Ended Six Months Ended , 20 20 201 9 20 20 201 9 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 154 $ 79 $ 233 $ 158 Performance obligations eliminated upon termination 2,572 — 2,572 — New activities in the period from performance obligations satisfied: Performance obligations satisfied 147 649 187 676 Total revenue from performance obligations satisfied or eliminated $ 2,873 $ 728 $ 2,992 $ 834

Note 5 - Long-term Debt

Note 5 - Long-term Debt	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	5. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. In connection with the Loan Agreement, on May 30, 2019, 9 As of June 30, 2020, three June 30, 2020, six June 30, 2020. Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. June 30, 2020, March 31, 2020. June 30, 2020

Note 6 - Leases

Note 6 - Leases	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. The Company leases office and laboratory space for its corporate headquarters, located at 301 351 The components of lease expense are presented in the following table (in thousands): Three Months Ended Six Months Ended , 20 20 201 9 20 20 201 9 Operating lease costs $ 269 $ 340 $ 609 $ 680 Sublease income (149 ) (150 ) (299 ) (296 ) Net lease costs $ 120 $ 190 $ 310 $ 384 The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: June 30 , 20 20 Weighted-average remaining term – operating lease (years) 3.58 Weighted-average discount rate – operating lease 11.72 % Future minimum lease payments as of June 30, 2020 Year: 2020 (remaining six months) $ 634 2021 1,364 2022 1,345 2023 1,386 2024 116 Total future minimum lease payments 4,845 Less imputed interest (677 ) Total $ 4,168 Reported as: Operating lease liabilities $ 1,076 Operating lease liabilities, net of current portion 3,092 Total lease liability $ 4,168 Future minimum sublease payments as of June 30, 2020 Year: 2020 (remaining six months) $ 297 2021 610 2022 629 2023 648 2024 54 Total future minimum sublease payments $ 2,238 The rent receivable balance is reported in the balance sheet as follows (in thousands): Reported as: Prepaid expenses and other current assets $ 87 Other assets 307 Total rent receivable $ 394

Note 7 - Liability Related to S

Note 7 - Liability Related to Sale of Future Royalties	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	7. In September 2015, first four 80% The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the three June 30, 2019, $65.0 three June 30, 2020, November 14, 2020. may The change in estimate reduced the effective interest rate over the life of the liability to 0% by recording interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rates for both the three six June 30, 2020 three June 30, 2019, three six June 30, 2019. three June 30, 2019 six June 30, 2019 The following table shows the activity within the liability account for the six June 30, 2020 ( Six months ended June 30 , 20 20 Period from inception to June 30 , 20 20 Liability related to sale of future royalties — beginning balance $ 92,035 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (156 ) (840 ) Non-cash interest (income) expense recognized (1,677 ) 29,858 Liability related to sale of future royalties as of June 30, 2020 90,202 90,202 Less: current portion (160 ) (160 ) Liability related to sale of future royalties — net of current portion $ 90,042 $ 90,042 As royalties are remitted to PDL from ARPI LLC, as described in Note 1 10 December 31, 2019,

Note 8 - Legal Proceedings

Note 8 - Legal Proceedings	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	8. As previously disclosed, several lawsuits were filed in connection with the Company’s proposed acquisition of Tetraphase. Following termination of the Merger Agreement, each of the merger-related complaints naming the Company as a defendant were voluntarily dismissed on or about June 9, 2020.

Note 9 - Warrants

Note 9 - Warrants	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Warrants Disclosure [Text Block]	9. Loan Agreement Warrants In connection with the Loan Agreement, on May 30, 2019, June 30, 2020, not May 2029.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Common Stock ATM Agreement The Company has entered into a Controlled Equity Offering SM may May 9, 2019, may During the three six June 30, 2020, June 30, 2020, New and Amended Stock Plans 20 20 Equity Incentive Plan On June 16, 2020, 2020 2020 2020 As of June 16, 2020, no may 2011 2011 2011 2011 The initial aggregate number of shares of the Company’s common stock issuable pursuant to stock awards under the 2020 2006 2011 not 2020 not not Amended and Restated 2011 Additionally, on June 16, 2020, 2011 2011 2011

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	1 1 . Stock-Based Compensation The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended 2011 Three Months Ended Six Months Ended 20 20 201 9 20 20 201 9 Cost of goods sold $ 27 $ 68 $ 73 $ 129 Research and development 184 233 384 457 Selling, general and administrative 879 1,045 1,779 1,867 Total $ 1,090 $ 1,346 $ 2,236 $ 2,453 As of June 30, 2020, 2011

Note 12 - Net Loss Per Share of

Note 12 - Net Loss Per Share of Common Stock	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	1 2 . Net Loss per Share of Common Stock The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: June 30 , 20 20 201 9 ESPP, RSUs and stock options to purchase common stock 14,816,721 14,090,688 Common stock warrants 176,679 176,679

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event Registered Direct Offering On July 23, 2020, No

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA ® TM ® November 2, 2018, first 2019. June 2018, not may one not The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. Although Zalviso was approved for sale in Europe on September 18, 2015, third November 2018 first 2019. DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Grünenthal Amended Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 14, 2020. On May 20, 2020, first third Termination of Proposed Acquisition of Tetraphase Pharmaceuticals, Inc. On March 15, 2020, May 27, 2020 May 29, 2020, On June 4, 2020, Co-Promotion Agreement On March 15, 2020, 15 not one July 28, 2020, no three six June 30, 2020.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, ARPI LLC, which was formed in September 2015 7
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior year amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year's presentation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three six June 30, 2020, not may December 31, 2020. December 31, 2019, December 31, 2019, 10 10 December 31, 2019,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Restructuring Costs The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. On March 16, 2020, six June 30, 2020, The headcount reduction was completed in the first 2020. No
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments – Credit Losses , ” 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022.

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of June 30 , 2020 Amortized Cost Gross Unrealized Gross Unrealized Fair Cash and cash equivalents: Cash $ 4,660 $ — $ — $ 4,660 Money market funds 1,334 — — 1,334 U.S. government agency securities 5,999 — — 5,999 Commercial paper 9,796 — — 9,796 Total cash and cash equivalents 21,789 — — 21,789 Short-term investments: U.S. government agency securities 13,052 — — 13,052 Commercial paper 8,845 — — 8,845 Total short-term investments 21,897 — — 21,897 Total cash, cash equivalents and short-term investments $ 43,686 $ — $ — $ 43,686 As of December 31, 2019 Amortized Cost Gross Unrealized Gross Unrealized Fair Cash and cash equivalents: Cash $ 1,957 $ — $ — $ 1,957 Money market funds 598 — — 598 Commercial paper 12,129 — — 12,129 Total cash and cash equivalents 14,684 — — 14,684 Short-term investments: U.S. government agency securities 14,268 — — 14,268 Commercial paper 27,131 — — 27,131 Corporate debt securities 10,054 — — 10,054 Total short-term investments 51,453 — — 51,453 Total cash, cash equivalents and short-term investments $ 66,137 $ — $ — $ 66,137
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of June 30 , 2020 Fair Value Level I Level II Level III Assets Money market funds $ 1,334 $ 1,334 $ — $ — U.S. government agency securities 19,051 — 19,051 — Commercial paper 18,641 — 18,641 — Total assets measured at fair value $ 39,026 $ 1,334 $ 37,692 $ — Liabilities Contingent put option liability $ 591 $ — $ — $ 591 Total liabilities measured at fair value $ 591 $ — $ — $ 591 As of December 31, 2019 Fair Value Level I Level II Level III Assets Money market funds $ 598 $ 598 $ — $ — U.S. government agency securities 14,268 — 14,268 — Commercial paper 39,260 — 39,260 — Corporate debt securities 10,054 — 10,054 — Total assets measured at fair value $ 64,180 $ 598 $ 63,582 $ — Liabilities Contingent put option liability $ 437 $ — $ — $ 437 Total liabilities measured at fair value $ 437 $ — $ — $ 437
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months 20 Six Months 20 Fair value—beginning of period $ 746 $ 437 Fair value of contingent put option associated with the Loan Agreement (155 ) 154 Fair value—end of period $ 591 $ 591 Three Months Six Months Fair value—beginning of period $ 98 $ 121 Fair value of contingent put option associated with the Loan Agreement 657 657 Change in fair value of contingent put option associated with the Prior Agreement (98 ) (121 ) Fair value—end of period $ 657 $ 657

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of June 30 , 20 20 December 31, 201 9 Raw materials $ 693 $ 1,153 Work-in-process — 593 Finished goods 1,946 1,549 Total $ 2,639 $ 3,295

Note 4 - Revenue from Contrac_2

Note 4 - Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Product sales: DSUVIA $ 2 $ 157 Zalviso 301 420 Total product sales 303 577 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 37 121 Royalty revenue 12 40 Other revenue 2,572 2,572 Total revenues from contract and other collaboration 2,621 2,733 Total revenue $ 2,924 $ 3,310 Three Months Ended June 30, 20 19 Six Months Ended June 30, 20 19 Product sales: DSUVIA $ 55 $ 102 Zalviso 713 792 Total product sales 768 894 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 118 203 Royalty revenue 40 67 Other revenue 15 42 Total revenues from contract and other collaboration 173 312 Total revenue $ 941 $ 1,206
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Amended Agreements $ 3,148 $ — $ (2,805 ) $ 343 Deferred revenue – Other 96 — (96 ) — Deferred revenue $ 3,244 $ — $ (2,901 ) $ 343 Three Months Ended Six Months Ended , 20 20 201 9 20 20 201 9 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 154 $ 79 $ 233 $ 158 Performance obligations eliminated upon termination 2,572 — 2,572 — New activities in the period from performance obligations satisfied: Performance obligations satisfied 147 649 187 676 Total revenue from performance obligations satisfied or eliminated $ 2,873 $ 728 $ 2,992 $ 834

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Six Months Ended , 20 20 201 9 20 20 201 9 Operating lease costs $ 269 $ 340 $ 609 $ 680 Sublease income (149 ) (150 ) (299 ) (296 ) Net lease costs $ 120 $ 190 $ 310 $ 384 June 30 , 20 20 Weighted-average remaining term – operating lease (years) 3.58 Weighted-average discount rate – operating lease 11.72 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2020 (remaining six months) $ 634 2021 1,364 2022 1,345 2023 1,386 2024 116 Total future minimum lease payments 4,845 Less imputed interest (677 ) Total $ 4,168 Operating lease liabilities $ 1,076 Operating lease liabilities, net of current portion 3,092 Total lease liability $ 4,168
Lessee, Operating Sublease, to Be Received, Maturity [Table Text Block]	Year: 2020 (remaining six months) $ 297 2021 610 2022 629 2023 648 2024 54 Total future minimum sublease payments $ 2,238 Reported as: Prepaid expenses and other current assets $ 87 Other assets 307 Total rent receivable $ 394

Note 7 - Liability Related to_2

Note 7 - Liability Related to Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Other Liabilities [Table Text Block]	Six months ended June 30 , 20 20 Period from inception to June 30 , 20 20 Liability related to sale of future royalties — beginning balance $ 92,035 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (156 ) (840 ) Non-cash interest (income) expense recognized (1,677 ) 29,858 Liability related to sale of future royalties as of June 30, 2020 90,202 90,202 Less: current portion (160 ) (160 ) Liability related to sale of future royalties — net of current portion $ 90,042 $ 90,042

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Six Months Ended 20 20 201 9 20 20 201 9 Cost of goods sold $ 27 $ 68 $ 73 $ 129 Research and development 184 233 384 457 Selling, general and administrative 879 1,045 1,779 1,867 Total $ 1,090 $ 1,346 $ 2,236 $ 2,453

Note 12 - Net Loss Per Share _2

Note 12 - Net Loss Per Share of Common Stock (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30 , 20 20 201 9 ESPP, RSUs and stock options to purchase common stock 14,816,721 14,090,688 Common stock warrants 176,679 176,679

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) $ in Millions	Jun. 04, 2020USD ($)	Mar. 16, 2020	Jun. 30, 2020USD ($)	Mar. 15, 2020
Co-Promotion Agreement, Percent of Net Sales to be Paid as Royalty Contingent on Performance Standards				10.00%
Restructuring and Related Cost, Number of Positions Eliminated		30
Restructuring Charges, Total			$ 0.5
Tetraphase [Member] | AcelRX [Member]
Business Acquisition, Termination Fee	$ 1.8

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities, Total			$ 0		$ 0
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	$ 0	$ 0	0	$ 0
OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax	$ 0	$ 0	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Amortized Cost	$ 43,686	$ 66,137
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	43,686	66,137
Cash and Cash Equivalents [Member]
Amortized Cost	21,789	14,684
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	21,789	14,684
Cash and Cash Equivalents [Member] | Cash [Member]
Amortized Cost	4,660	1,957
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	4,660	1,957
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Amortized Cost	1,334	598
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	1,334	598
Cash and Cash Equivalents [Member] | U.S. Government Agency Securities [Member]
Amortized Cost		14,268
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		14,268
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Amortized Cost	9,796	12,129
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	9,796	12,129
Marketable Securities [Member]
Amortized Cost	21,897	51,453
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	21,897	51,453
Marketable Securities [Member] | U.S. Government Agency Securities [Member]
Amortized Cost	5,999
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	5,999
Marketable Securities [Member] | Commercial Paper [Member]
Amortized Cost	8,845	27,131
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	8,845	27,131
Marketable Securities [Member] | US Government Agencies Debt Securities [Member]
Amortized Cost	13,052
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	$ 13,052
Marketable Securities [Member] | Corporate Debt Securities [Member]
Amortized Cost		10,054
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		$ 10,054

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets, fair value	$ 39,026	$ 64,180
Liabilities, fair value	591	437
Contingent Put Option Liability [Member]
Liabilities, fair value	591	437
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	1,334	598
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	37,692	63,582
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	591	437
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	591	437
Money Market Funds [Member]
Assets, fair value	1,334	598
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	1,334	598
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member]
Assets, fair value	19,051	14,268
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	19,051	14,268
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	18,641	39,260
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	18,641	39,260
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0	0
Corporate Debt Securities [Member]
Assets, fair value		10,054
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		10,054
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Fair value, Beginning of period	$ 746	$ 98	$ 437	$ 121
Fair value of contingent put option associated with the Loan Agreement	(155)	657	154	657
Change in fair value of contingent put option associated with the Prior Agreement		(98)		(121)
Fair value, End of period	$ 591	$ 657	$ 591	$ 657

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Inventory Write-down	$ 0.3	$ 0.4
Terminated Amended Agreements [Member]
Inventory Write-down		0.3
DSUVIA [Member]
Inventory Write-down		$ 0.1

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Raw materials	$ 693	$ 1,153
Work-in-process	0	593
Finished goods	1,946	1,549
Total	$ 2,639	$ 3,295	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Note 4 - Revenue from Contrac_3

Note 4 - Revenue from Contracts with Customers (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jul. 17, 2015
Deferred Revenue, Current, Total		$ 300		$ 300
Amended License Agreement [Member]
Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets						$ 194,500
Contract with Customer, Liability, Liability Eliminated		$ 2,572	$ 0	$ 2,572	$ 0
Amended License Agreement [Member] | Based upon Successful Regulatory and Product Development Efforts [Member]
Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets						28,500
Amended License Agreement [Member] | Based upon Net Sales Target Achievements [Member]
Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets						$ 166,000
ZALVISO [Member]
Contract with Customer, Liability, Liability Eliminated	$ 2,600

Note 4 - Revenue from Contrac_4

Note 4 - Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue	$ 2,924	$ 941	$ 3,310	$ 1,206
DSUVIA [Member]
Revenue	2	55	157	102
ZALVISO [Member]
Revenue	301	713	420	792
Product [Member]
Revenue	303	768	577	894
Non-cash Royalty [Member]
Revenue	37	118	121	203
Royalty [Member]
Revenue	12	40	40	67
Contract and Other Revenue [Member]
Revenue	2,572	15	2,572	42
Contract and Other Collaboration [Member]
Revenue	$ 2,621	$ 173	$ 2,733	$ 312

Note 4 - Revenue from Contrac_5

Note 4 - Revenue from Contracts with Customers - Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Contract Liabilities: Deferred Revenue				$ 3,244
Contract Liabilities: Deferred Revenue, Additions				0
Contract Liabilities: Deferred Revenue, Deductions				(2,901)
Contract Liabilities: Deferred Revenue		$ 343		343
Revenue		2,924	$ 941	3,310	$ 1,206
ZALVISO [Member]
Contract Liabilities: Deferred Revenue				3,148
Contract Liabilities: Deferred Revenue, Additions				0
Contract Liabilities: Deferred Revenue, Deductions				(2,805)
Contract Liabilities: Deferred Revenue		343		343
Amounts included in contract liabilities at the beginning of the period: Performance obligations eliminated upon termination	$ 2,600
Revenue		301	713	420	792
Amended License Agreement [Member]
Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied		154	79	233	158
Amounts included in contract liabilities at the beginning of the period: Performance obligations eliminated upon termination		2,572	0	2,572	0
New activities in the period from performance obligations satisfied: Performance obligations satisfied		147	649	187	676
Revenue		2,873	$ 728	2,992	$ 834
Product and Service, Other [Member]
Contract Liabilities: Deferred Revenue				96
Contract Liabilities: Deferred Revenue, Additions				0
Contract Liabilities: Deferred Revenue, Deductions				(96)
Contract Liabilities: Deferred Revenue		$ 0		$ 0

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2019	May 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Repayments of Long-term Debt, Total					$ 0	$ 3,470
Interest Expense, Total			$ 872	$ 500	1,727	876
Amortization of Debt Discount (Premium)					558	$ 234
Leasehold Improvements [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total			1,700		1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement			$ 2,000		$ 2,000
Debt Instrument, Interest Rate, Effective Percentage			14.35%		14.35%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount		$ 25,000
Repayments of Long-term Debt, Total		8,900
Proceeds from Debt, Net of Issuance Costs and Repayment of Debt		$ 15,900
Long-term Debt, Total			$ 24,700		$ 24,700
Interest Expense, Total			900		1,700
Amortization of Debt Discount (Premium)			$ 300		$ 500

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual)	Jun. 30, 2020
Percentage of Office and Laboratory Space Sublease	47.00%

Note 6 - Leases - Operating Lea

Note 6 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating lease costs	$ 269	$ 340	$ 609	$ 680
Sublease income	(149)	(150)	(299)	(296)
Net lease costs	$ 120	$ 190	$ 310	$ 384
Weighted-average remaining term – operating lease (years) (Year)	3 years 6 months 29 days		3 years 6 months 29 days
Weighted-average discount rate – operating lease	11.72%		11.72%

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	[1]
2020 (remaining six months)	$ 634
2021	1,364
2022	1,345
2023	1,386
2024	116
Total future minimum lease payments	4,845
Less imputed interest	(677)
Total	4,168
Operating lease liabilities	1,076	$ 970
Operating lease liabilities, net of current portion	3,092	$ 3,640
Total lease liability	$ 4,168
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Note 6 - Leases - Future Minimu

Note 6 - Leases - Future Minimum Sublease Payments (Details) $ in Thousands	Jun. 30, 2020USD ($)
2020 (remaining six months)	$ 297
2021	610
2022	629
2023	648
2024	54
Total future minimum sublease payments	2,238
Rent receivable	394
Prepaid Expenses and Other Current Assets [Member]
Rent receivable	87
Other Assets [Member]
Rent receivable	$ 307

Note 7 - Liability Related to_3

Note 7 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Sep. 18, 2015	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Proceeds From Sale of Royalty and Milestone Rights	$ 65
Royalty Arrangment Maximum Payments	$ 195
Prospective Average Rate for Remaining Term of the Agreement			4.20%
Contingent Gain (Loss) on Royalty Monetization Arrangement				$ 65
Effective Interest Over Life of Liability Related to Sale of Future Royalties				0.00%
Effective Annual Interest Rate		4.00%	4.20%		1.40%
Net Income (Loss) from Change Estimate on Liability Related to Sale of Future Royalties			$ (2.7)
Net Income (Loss) Per Share, Change Estimate on Liability Related to Sale of Future Royalties (in dollars per share)			$ (0.03)
PDL [Member]
Percentage of Royalties and Rights Under Agreement	75.00%
PDL [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement	80.00%
Commercial Milestones Value Maximum Amount Available	$ 35.6
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available	$ 44.5

Note 7 - Liability Related to_4

Note 7 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		57 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	[1]
Liability related to sale of future royalties — beginning balance			$ 92,035		$ 0
Proceeds from sale of future royalties			0		61,184
Non-cash royalty revenue			(156)		(840)
Non-cash interest (income) expense recognized	$ (834)	$ (996)	(1,677)	$ 611	29,858
Liability related to sale of future royalties as of June 30, 2020	90,202		90,202		90,202
Less: current portion	(160)		(160)		(160)	$ (352)
Liability related to sale of future royalties — net of current portion	$ 90,042		$ 90,042		$ 90,042	$ 91,683
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019.

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - Warrant In Connection with Oxford Finance Loan Agreement [Member] - $ / shares	Jun. 30, 2020	May 30, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.83
Class of Warrant or Right, Outstanding (in shares)	176,679

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details Textual) - USD ($) $ in Thousands	Jun. 16, 2020	May 09, 2019	Jun. 21, 2016	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020
Stock Issued During Period, Value, New Issues				$ 665	$ 784
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	5,500,000
The 2020 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares to be Added (in shares)	14,892,170
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,900,000
ATM Agreement [Member]
Proceeds from Issuance Initial Public Offering		$ 80,000	$ 40,000
Aggregate Offering Price, Increase During Period		$ 40,000
Stock Issued During Period, Shares, New Issues (in shares)				445,000		876,800
Stock Issued During Period, Value, New Issues				$ 700		$ 1,500
Aggregate Offering Price, Maximum						$ 43,800

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual)	Jun. 30, 2020shares
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	5,775,140
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	13,026,080
The 2020 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	1,444,095
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	4,900,000

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-based compensation expense	$ 1,090	$ 1,346	$ 2,236	$ 2,453
Cost of Sales [Member]
Stock-based compensation expense	27	68	73	129
Research and Development Expense [Member]
Stock-based compensation expense	184	233	384	457
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 879	$ 1,045	$ 1,779	$ 1,867

Note 12 - Net Loss Per Share _3

Note 12 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	14,816,721	14,090,688
Warrant [Member]
Antidilutive securities (in shares)	176,679	176,679

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Jul. 23, 2020	Jun. 30, 2020	Jun. 30, 2019
Proceeds from Issuance of Common Stock		$ 1,449,000	$ 0
Subsequent Event [Member] | Private Placement [Member] | Armistice Capital and Rock Springs Capital [Member]
Stock Issued During Period, Shares, New Issues (in shares)	9,433,962
Shares Issued, Price Per Share (in dollars per share)	$ 1.06
Proceeds from Issuance of Common Stock	$ 10,000,000
Estimated Offering Costs	$ 25,000